Abstract CT180: Preliminary phase 1 profile of BMS-986179, an anti-CD73 antibody, in combination with nivolumab in patients with advanced solid tumors
Authors: Lillian L. Siu, Howard Burris, Dung T. Le, Antoine Hollebecque, Neeltje Steeghs, Jean-Pierre Delord, John Hilton, Bryan Barnhart, Emanuela Sega, Kinjal Sanghavi, Anke Klippel, Cyrus Hedvat, Ed Hilt, Mark Donovan, Adrianna Gipson, Paul Basciano, Jennifer Postelnek, Yue Zhao, Raymond P. Perez, Richard D. Carvajal
Journal: Cancer Research (2018)

Abstract Background: CD73 is an ectonucleotidase that converts adenosine monophosphate to adenosine, a potent immunosuppressive soluble mediator that inhibits the cytotoxic function of CD8+ T cells and natural killer cells while promoting proliferation of immunosuppressive cells. BMS-986179 is a high-affinity antibody that inhibits CD73 enzymatic activity and downregulates its expression on tumor cells. Blockade of CD73 enhanced the antitumor activity of anti-PD-1 in preclinical models (Barnhart BC, et al. Cancer Res. 2016;76(14 suppl) [abstract 1476]). Here we describe preliminary results of the first-in-human phase 1/2a study of BMS-986179 + nivolumab (NIVO) in patients (pts) with advanced solid tumors (NCT02754141). Methods: Pts with ≥ 1 prior therapy were treated in this open-label, dose-escalation and -expansion study. Escalation began with a 2-week monotherapy lead-in, in which pts received BMS-986179 150-1600 mg IV QW followed by BMS-986179 (same dose) IV QW + NIVO 240 mg IV Q2W. Pharmacokinetics (PK), pharmacodynamics (PD), safety, and preliminary antitumor activity were evaluated. PD analyses included immunohistochemistry, enzyme activity assays in tumor biopsies, and evaluation of receptor occupancy and soluble CD73 in peripheral blood. Results: As of the Dec 19, 2017, data cutoff, 59 pts were treated with BMS-986179 ± NIVO during dose escalation. PK of BMS-986179 was nonlinear at lower doses due to target-mediated drug disposition, and exposure increased proportionally from 1200 to 1600 mg. BMS-986179 demonstrated complete and persistent CD73 target engagement in the tumor and periphery at all doses. Treatment-related AEs (TRAEs) were observed in 30 of 52 pts (58%) who received the combination, with no clear dose relationship. Only 8 pts (15%) experienced grade 3 TRAEs, and 1 discontinued treatment due to a TRAE (grade 3 increased ALT). Both the monotherapy lead-in and the combination were well tolerated, with no grade 4 TRAEs and no treatment-related deaths. BMS-986179 efficiently inhibited CD73 enzyme activity in the tumor vasculature and tumor cells at all doses, without dose dependency. Overall, 7 pts with head and neck, pancreatic, prostate, anal, and renal cancer achieved confirmed partial responses and 10 pts had stable disease. Conclusions: BMS-986179 + NIVO was well tolerated, with CD73 target engagement in the tumor and periphery and a safety profile similar to that of NIVO monotherapy. The combination demonstrated preliminary antitumor activity. These data support the ongoing evaluation of this combination in pts with advanced solid tumors. Citation Format: Lillian L. Siu, Howard Burris, Dung T. Le, Antoine Hollebecque, Neeltje Steeghs, Jean-Pierre Delord, John Hilton, Bryan Barnhart, Emanuela Sega, Kinjal Sanghavi, Anke Klippel, Cyrus Hedvat, Ed Hilt, Mark Donovan, Adrianna Gipson, Paul Basciano, Jennifer Postelnek, Yue Zhao, Raymond P. Perez, Richard D. Carvajal. Preliminary phase 1 profile of BMS-986179, an anti-CD73 antibody, in combination with nivolumab in patients with advanced solid tumors [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr CT180.